At variance with insulin, ABA does not induce hypoglycemia, even at a dose 100,000 times higher than the one efficacious in reducing glycemia (100 mg/Kg BW vs. 1 μg/Kg BW); thus, it has a very high therapeutic index; the absence of hypoglycemic risk due to excess dosage places ABA at significant variance with respect to insulin and to oral hypoglycemic drugs. Here, INS is linked to Hypoglycemia.